Palvella Therapeutics, Inc. · NASDAQ:PVLA

Palvella Therapeutics — Pieris Pharmaceuticals — AACR 2021

18 slides from Palvella Therapeutics's conference presentation, Apr 10, 2021

  1. Slide 1: Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule

    Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies Sarina Piha-Paul, MD University of Texas, MD Anderson Cancer Center Houston, TX

  2. Slide 2: Disclosure Information

    Disclosure Information My Disclosures: l receive the following Clinical Trial Research Support/Grant Funding through the institution: AbbVie, Inc.; ABM Therapeutics, Inc.; Acepodia, Inc; Alkermes; Aminex Therapeutics; Amphivena Therapeutics, Inc.; BioMarin Pharmaceutical, Inc; Boehringer Ingelheim;

  3. Slide 3: Unique Attributes of 4-1BB Agonism

    Unique Attributes of 4-1BB Agonism APC Cell membrane Proliferation Cytotoxicity MHC-peptide 4-1BBL trimers Cytokine Secretion << Signal 1 >> << Signal 2 >> 4-1BB TCR Th1 Polarization upregulation 4-1BB by <<Signal1>> Memory Formation Cell membrane TRAF2 TRAF2 T cell Survival TRAF1 T cell Resistance

  4. Slide 4: PRS-343 (Cinrebafusp alfa): HER2 x 4-1BB Bispecific

    PRS-343 (Cinrebafusp alfa): HER2 x 4-1BB Bispecific Drives 4-1BB Agonism in the Tumor Microenvironment of HER2+ Solid Tumors CLINICALLY-RELEVANT HER2-targeting moiety of the drug 4-1BB cross-linking ameliorates BIOMARKERS localizes to the tumor microenvironment T-cell exhaustion and is critical and

  5. Slide 5: Ph 1 Monotherapy PRS-343 Study

    Ph 1 Monotherapy PRS-343 Study Study Objectives Primary: Characterize Safety Profile Dose Escalation 18 mg/kg (n = 9) Identify MTD or RP2D Study Design 12 mg/kg (n = 3) 8 mg/kg (n = 26) Secondary: Characterize PK/PD & Immunogenicity Preliminary anti-tumor activity 5 mg/kg (n = 9) 2.5 mg/kg (n = 6) *

  6. Slide 6: Baseline Characteristics (N = 78)

    Baseline Characteristics (N = 78) Characteristic n (%) Primary Cancer Type n (%) Age, Median (range) 63 (24–92) Gastroesophageal 34 (44%) Gender F 46 (59%) Breast 16 (21%) M 32 (41%) ECOG PS Colorectal 12 (15%) 0 19 (24%) 1 59 (76%) Gynecological 9 (12%) Prior Therapy Lines 1 11 (14%) Bladder 2 (3%)

  7. Slide 7: Treatment Related Adverse Events at Active Doses (≥ 2.5 mg/kg)

    PRS-343 Treatment Related Adverse Events at Active Doses (≥ 2.5 mg/kg) Treatment Related Adverse Events All Grades Grade 1-2 Grade 3-4 (TRAEs occurring in > 1 patient; n = 53) n (%) n (%) n (%) Infusion related reaction 13 (25%) 9 (17%) 4 (8%) Nausea 7 (13%) 7 (13%) Chills 6 (11%) 6 (11%) Vomiting 6

  8. Slide 8: PRS-343 Efficacy Data Overview

    PRS-343 Efficacy Data Overview Cohort 13b 12b 11c Obi 11b 11 10 9 Total 18 mg/kg, 12 mg/kg, 8 mg/kg, 8 mg/Kg, 8 mg/kg, 8 mg/kg, 5 mg/kg, 2.5 mg/kg, Best Response Q2W Q2W QW Q2W Q2W Q3W Q3W Q3W Evaluable Patients 8 2 5 4 7 4 7 5 42 CR 1 1 PR 1 3 4 SD 3 1 2 3 3 3 2 17 ORR 25% 0% 0% 0% 43% 0% 0% 0% 12%

  9. Slide 9: Efficacy Data: Analysis of Patients Treated at Active Doses

    PRS-343 Efficacy Data: Analysis of Patients Treated at Active Doses Overall Population Data Cut-off: 25 Feb 2021 DO NOT POST

  10. Slide 10: Efficacy Data: GC/GEJ & Colorectal Cancers

    PRS-343 Efficacy Data: Analysis of Patients Treated at Active Doses GC/GEJ & Colorectal Cancers Data Cut-off: 25 Feb 2021 DO NOT POST

  11. Slide 11: Durable Responses with PRS-343 among Heavily Pre-treated Population

    Durable Responses with PRS-343 among Heavily Pre-treated Population Overall Population Data Cut-off: 25 Feb 2021 DO NOT POST

  12. Slide 12: Generates Immunogenic Responses

    PRS-343 Generates Immunogenic Responses Gastric Cancer Patient with Partial Response Rectal Cancer Patient with Complete Response • 80-year-old woman; initial diagnosis in June 2017 • 59-year-old male; initial diagnosis in March 2017 • Gastric adenoca with mets to liver, LN and adrenals • Rectal can

  13. Slide 13: Shows Dose Dependent Activity across Key Pharmacodynamic Parameters

    PRS-343 Shows Dose Dependent Activity across Key Pharmacodynamic Parameters Serum (s4-1BB) Tumor (CD8+) Connects group averages Median Mann-Whitney U test Dose at 8 mg/kg incorporates patients treated at Q1W, Q2W or Q3W DO NOT POST

  14. Slide 14: Activates Adaptive and Innate Immunity in the Tumor

    PRS-343 Activates Adaptive and Innate Immunity in the Tumor Biopsy Biopsy Pre-dose PRS-343 PRS-343 Post-dose (Cycle 1 Day 1) (Cycle 2 Day 1) (Cycle 2 Days 2-8) Based on preclinical and clinical data, serum concentration of > 20 µg/ml defines active dose range beginning at 2.5 mg/kg (Cohort 9) CD8+ c

  15. Slide 15: Shows Clinical Activity in Both Hot and Cold Tumors

    PRS-343 Shows Clinical Activity in Both “Hot” and “Cold” Tumors PD-L1 status and CD8+ T cells levels in tumor biopsies CD8 Low/PD-L1 High Hot Tumor & PD-L1 High CR PR SD Cold Tumor CD8 High/PD-L1 Low/Negative * * Threshold informed by (Tumeh et al., 2014 and Blando et al., 2019​) Several patients wi

  16. Slide 16: Shows Signs of Preclinical and Clinical Activity in the HER-2 Low Setting

    PRS-343 Shows Signs of Preclinical and Clinical Activity in the HER-2 Low Setting PRS-343 enhances T cell activation in in vitro PRS-343 increases soluble 4-1BB in co-cultures with HER-2 low tumor cell lines* HER-2 low-expressing patients JIMT-1 60 Her 2 IHC 2+ Her 2 IHC 2+ fold-induction to baselin

  17. Slide 17: Summary Conclusions

    Summary Conclusions  Monotherapy PRS-343 is well tolerated and safe up to 18 mg/kg • No significant specific anti-HER2 or anti-4-1BB safety signal • No dose limiting toxicity identified  Dose-dependent Immune activation demonstrated • Increase in CD8+ T cell, NK cells and cytotoxic activity in ​tu

  18. Slide 18: Acknowledgements

    Acknowledgements Patients, their families and caregivers Investigators, as well as their site personnel Sarina Piha-Paul, MD Anderson Cancer Center, Houston, TX Johanna Bendell, Sarah-Canon Research Institute, Nashville, TN Anthony Tolcher, NEXT Oncology, San Antonio, TX Rachna T. Shroff, University

Pieris Pharmaceuticals — AACR 2021 on 6ix